A newly released real-world study published in Musculoskeletal Care, showed that Apos® treatment helped knee-surgery candidates avoid surgery and improved clinical outcomes, such as reductions in pain, for three years.1
The new study was a follow up to an earlier 2-year study2 that demonstrated that 84% of patients with severe knee osteoarthritis (OA) treated with Apos® avoided surgery over the course of the two years. The results of this analysis over three years confirmed the continued effectiveness of the Apos® solution. It demonstrated that 74% of patients with severe knee OA treated with Apos® continued to avoid surgery for the additional third year of this study. Patients’ feedback shows that not only did most avoid surgery, but they also reported better clinical outcomes. Notably, on average, they experienced 59.6% less pain, and 51.9% better function following treatment with Apos®.
Harry Leider, MD, MBA, AposHealth®’s Chief Medical Officer commented: “Knee osteoarthritis is a common condition and often progresses, requiring expensive total knee replacement surgery and related clinical interventions. This important study confirms the impressive longer-term clinical and economic results of treatment of moderate to severe knee osteoarthritis with the Apos® device and establishes Apos® as a compelling core component of a care management program for musculoskeletal disease.”
Patients with end-stage knee osteoarthritis were calibrated (i.e., fitted in a customized manner depending on their gait and pain) with a non-invasive shoe-like biomechanical device (Apos®) and utilized it for short periods of time during daily activity. They then returned for clinic visits at specific intervals for assessment and to modify their treatment as necessary. Of the 365 patients enrolled in the study and program, 270 avoided surgery after three years (74%). Of them, nine patients (2%) passed away during this period and did not have surgery. Ninety-five patients (26%) had a total knee replacement (TKR) surgery in the three years since the beginning of the intervention. Over the three years of the study, 23 patients (6%) progressed to TKR within the first year, 36 patients (10%) within the second year, and 36 patients (10%) had a TKR during their third year of treatment.
At AposHealth, we are passionate about revolutionizing the treatment of musculoskeletal conditions simply, by addressing peoples’ gait and pain – to help them move better and live better. Our flagship solution, Apos®, is FDA-cleared to temporarily reduce knee pain caused by osteoarthritis and has been used by over 120,000 patients. It can also be used as a general wellness device to help patients live well with chronic lower back and hip pain. With a 96% satisfaction rate,4 and over 40 peer-reviewed clinical studies, this system—consisting of gait analysis, a personalized foot-worn device, and a customized treatment plan—has helped patients worldwide move, live, and thrive. For more information, visit https://www.AposHealth.co.uk.
- Greene, A; et al. https://onlinelibrary.wiley.com/doi/10.1002/msc.1757
- Greene, A; et al. https://journaloei.scholasticahq.com/article/37664-surgery-avoidance-rates-among-total-knee-replacement-candidates-following-a-non-invasive-biomechanical-intervention-a-retrospective-cohort-study
- Felson, D; et al. https://doi.org/10.1002/art.1780300811
- Based on data captured at 3rd follow-up appointment and based on the commercial activity with National Health Service patients in the UK treated between 2019-2020 (N=106)